諾輝健康(06606.HK)共同臨時清盤人申請聆訊將於下週三舉行
諾輝健康(06606.HK)公佈,已於2025年7月8日正式向大法院立案共同臨時清 盤人申請及呈請。共同臨時清盤人申請的聆訊將於2025年8月6日上午10時在大法院進行。
共同臨時清盤人一經委任,將會繼續就公司2024年3月28日及2024年5月28日公告中提及的事項進行調查,並且探索潛在的重組方案。
公司股份已自2024年3月28日起於聯交所暫停買賣,並將繼續暫停買賣直至進一步通知爲止。(ca/u)
~
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.